Reframing Obesity for Healthspan: Why GLP-1/GIP medicines like semaglutide can be a long-term tool

Reframing Obesity for Healthspan: Why GLP-1/GIP medicines like semaglutide can be a long-term tool — not a quick fix

If healthspan is the goal — living more years feeling strong, mobile, and metabolically resilient — we need to talk about obesity differently. The old story ("just eat less, move more") ignores the biology. Obesity is a chronic, multifactorial disease with powerful genetic, hormonal, and environmental drivers — and, like other chronic diseases, it often benefits from long-term medical therapy alongside nutrition, movement, sleep, and psychological support.

This is where incretin-based medicines come in: GLP-1 receptor agonists (e.g., semaglutide/Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound). They change physiology — appetite, satiety, gastric emptying — to shift energy balance in a way most people can feel. For many, they act like noise-cancelling headphones on hunger, creating the runway to build durable habits that extend healthspan.

• **Semaglutide 2.4 mg weekly** (with lifestyle support) produced ~15% mean weight loss in adults with overweight/obesity over 68 weeks (STEP-1, randomized controlled trial).
• **Tirzepatide** achieved ~16–23% mean weight loss at 72 weeks in SURMOUNT-1.
• **Beyond weight:** in people with established cardiovascular disease without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events versus placebo (SELECT).

**Key takeaway:** These are not cosmetic aids; they're disease-modifying therapies with benefits that matter for long-term health. That's healthspan.

When people stop GLP-1/GIP therapy, weight regain is common. In the STEP-4 withdrawal study, participants who continued semaglutide after a run-in maintained and deepened weight loss, while those switched to placebo regained much of it despite ongoing lifestyle support. Chronic disease → chronic treatment: that's the pattern we see across hypertension, dyslipidaemia — and now obesity.

That doesn't mean everyone must take these forever. It means we should plan for long-term management (whether with ongoing medication, structured maintenance strategies, or both) rather than 12-week sprints. The Endocrine Society has long framed obesity pharmacotherapy as an adjunct to comprehensive care that's appropriate long-term when effective and well-tolerated.

• They amplify your body's satiety signals (brain) and slow stomach emptying (gut), so you get full sooner and stay full longer.
• Over time, this leads to lower total intake without white-knuckle restraint.
• As weight falls, metabolic risk markers (blood pressure, lipids, liver fat) often improve; SELECT suggests CV risk reductions in high-risk patients.

**Common effects:** nausea, reflux, early fullness, constipation/diarrhoea, especially during dose escalations. Less common but important: gallbladder events; rare pancreatitis. These drugs carry a boxed warning for medullary thyroid carcinoma risk in rodents (avoid with personal/family history of MTC or MEN-2). Discuss your history with your clinician and escalate doses slowly. (See Australian product information and AusPAR for details.)

**Make the medication work for you:**

Eat protein-forward meals, add resistance training to preserve lean mass, prioritise sleep, and work with a clinician/dietitian — you'll likely feel better and keep more of the weight off. (Guidelines emphasise meds plus lifestyle, not either/or.)

• **Wegovy (semaglutide 2.4 mg)** is TGA-approved for chronic weight management and, since 2025, also for reducing CV events in people with overweight/obesity and established CVD.
• **PBS subsidy** for obesity indications remains not listed as of 31 Aug 2025 (cost considerations are ongoing), so out-of-pocket expense can be substantial.

If your biology keeps pulling you back to a higher set-point, willpower alone is an unfair fight. Treating obesity as a medical condition with medical tools isn't giving up — it's gearing up. For many, GLP-1/GIP therapy provides the stability to build keystone habits: strength training, protein-centred eating, fibre, walking after meals, better sleep. Those habits then compound into lower visceral fat, improved mobility, healthier BP and lipids, and fewer cardiovascular events — the stuff that extends the quality of your years.

**A realistic promise:**

• Medication can quiet the hunger noise and lower the biological headwinds.
• You bring the daily reps (food, movement, sleep, stress).
• Together, that's a healthspan engine — sustainable, compassionate, personalised.

• Assess candidacy (BMI + complications), medications, and medical history.
• Map a plan: dose-escalation schedule, side-effect mitigation, nutrition & training.
• Think long-term: if it works and is tolerated, plan for maintenance, not a stop-date.
• Review benefits beyond the scale: waist, labs, BP, sleep, mobility, quality of life. (All are part of healthspan.)

1. STEP-1: Once-weekly semaglutide in adults with overweight/obesity (NEJM). New England Journal of Medicine
2. STEP-4 withdrawal trial: continuing semaglutide maintained weight loss; stopping led to regain (JAMA + reviews). JAMA Network
3. SURMOUNT-1: Tirzepatide produced ~16–23% mean weight loss at 72 weeks (Diabetes Obes Metab/summary). dom-pubs.onlinelibrary.wiley.com
4. SELECT CV outcomes: Semaglutide 2.4 mg reduced MACE in people with CVD and overweight/obesity without diabetes (NEJM; ACC summary; Lancet analyses). New England Journal of Medicine, American College of Cardiology
5. Endocrine Society guidance: Obesity is chronic; pharmacotherapy as ongoing adjunct to lifestyle. Endocrine Society
6. TGA/AusPAR (Australia): Wegovy approval details and safety information. Therapeutic Goods Administration (TGA)
7. PBS status (Australia): As at 31 Aug 2025, semaglutide for obesity not listed on PBS (Medicine Status). pbs.gov.au
8. Obesity as multifactorial disease with strong genetic component (recent reviews). SpringerLink